EASD 2020 Highlights Podcast

Dr Rachel Giles guides us through 6 abstracts from the 56th EASD Annual Meeting:

1. Ertugliflozin offers some kidney protection – Cherney et al.
2. Empagliflozin significantly reduces CV and renal risk – Packer et al.
3. Once daily oral treatment with glucokinase activator TTP399 reduced HbA1c in patients with type 1 diabetes – Valcarce et al.
4. Diabetes still goes unnoticed, resulting in delayed diagnosis – Young et al.
5. Once-weekly insulin is a promising treatment option – Rosenstock et al.
6. Intermittent fasting: consuming fewer calories but in a different way – Varady et al.